Relationship between body mass index and 1 mg dexamethasone suppression test in patients with obesity
- 3 February 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3264-3272
Abstract
Aims: The 1 mg dexamethasone suppression test (DST) shows variable results in obesity, yet the impact of extreme obesity (body mass index [BMI] ≥50 kg/m 2 ) on hypothalamic–pituitary–adrenal axis function remains poorly characterized. This study evaluated post‐dexamethasone cortisol levels across distinct BMI categories and their associations with metabolic parameters. Materials and Methods: This retrospective study included 352 adults with obesity (BMI ≥30 kg/m 2 ) who underwent 1 mg overnight DST between February 2019 and August 2023. Patients were stratified into three groups: BMI 30.0–39.9 kg/m 2 ( n = 64), BMI 40.0–49.9 kg/m 2 ( n = 202), and BMI ≥50.0 kg/m 2 ( n = 86). Clinical, anthropometric, and laboratory parameters were compared between groups. Results: The cohort had a median age of 41 years and comprised 284 females (80.7%). Post‐dexamethasone cortisol levels showed modest differences across BMI categories (median 0.79, 0.77, and 0.88 μg/dL, respectively; p = 0.038). Inadequate cortisol suppression after the 1 mg dexamethasone test was rare, occurring in four patients (1.1%) overall: 0/64 (0%) in BMI 30.0–39.9 kg/m 2 , 2/202 (1.0%) in BMI 40.0–49.9 kg/m 2 , and 2/86 (2.3%) in BMI ≥50.0 kg/m 2 ; continuous BMI was not associated with post‐dexamethasone cortisol levels. Patients with super obesity demonstrated higher rates of hypertension (36% vs. 18.7–22.2%, p = 0.021) and diabetes (30.2% vs. 16.8–18.7%, p = 0.033). Conclusions: These findings emphasize that elevated post‐dexamethasone cortisol levels in patients with obesity should not be attributed to body weight alone but warrant appropriate evaluation for true hypercortisolism, with clinical interpretation guided by metabolic phenotype rather than BMI.Keywords
This publication has 7 references indexed in Scilit:
- Glucocorticoids and HPA axis regulation in the stress–obesity connection: A comprehensive overview of biological, physiological and behavioural dimensionsClinical Obesity, 2024
- Assessment of plasma dexamethasone levels after 1‐mg dexamethasone suppression test in adults with obesityClinical Endocrinology, 2024
- Serum cortisol level after low dose dexamethasone suppression test may be predictive for diabetes mellitus and hypertension presence in obese patients: A retrospective studyDiabetes Research and Clinical Practice, 2020
- In Obesity, HPA Axis Activity Does Not Increase with BMI, but Declines with Aging: A Meta-Analysis of Clinical StudiesPLOS ONE, 2016
- Performance of the 1 mg dexamethasone suppression test in patients with severe obesityObesity, 2016
- Increased Cortisol Bioavailability, Abdominal Obesity, and the Metabolic Syndrome in Obese WomenObesity Research, 2005
- Down-Regulation of Insulin Receptor Substrates (IRS)-1 and IRS-2 and Src Homologous and Collagen-Like Protein Shc Gene Expression by Insulin in Skeletal Muscle Is Not Associated with Insulin Resistance or Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2002